Abivax - ADR
ABVX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.13B
Close$
$7.59
91.5% downside
Current Fair Value
91.5% downsideOvervalued by 91.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $7.13 Billion |
|---|---|
| Enterprise Value | $6.74 Billion |
| Earnings per Share | $-4.65 |
| Beta | -0.25 |
| Outstanding Shares | 79,647,974 |
Return
| Return on Equity | -133.12% |
|---|---|
| Return on Assets | -105.49% |
| Return on Invested Capital | -104.99% |
Valuation & Multiples
| P/E Ratio | -16.78 |
|---|---|
| PEG | -101.6 |
| Price to Sales | - |
| Price to Book Ratio | 22.37 |
| Enterprise Value to Revenue | 3365.5 |
| Enterprise Value to EBIT | -16.44 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 21, 2026
EPS Estimate
$-0.98
Consensus analyst estimateRevenue Estimate
$799,166
Consensus analyst estimateNext Earnings Call
Expected Date
December 21, 2026
EPS Estimate
$-0.92
Consensus analyst estimateRevenue Estimate
$922,549
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 53.54% |
|---|---|
| Total Calls | 22,800▼ 99.70% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.80%▼ 77.25% |
|---|---|
| Total Invested | $141.04M▼ 98.04% |
| Investors Holding | 59▼ 309.00% |
About Abivax
69 employees
CEO: Marc de Garidel
Based in Paris, France, ABIVAX Société Anonyme is a biopharmaceutical company dedicated to the discovery and optimization of novel drug treatments. Their research and development efforts primarily target inflammatory conditions, infectio...